ThE_uNKNowN retweeted
Really glad to be done with this phase!😃
Grateful to God and the people that made this possible. Onto the next🥳
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
First ASCO. First year of residency.
Grateful to have two first-author abstracts accepted, one poster presentation, and five additional abstracts as a co-author at this year’s ASCO Annual Meeting.
Thankful for the mentorship, collaboration, and opportunities that made this possible. Excited to continue contributing to oncology research and patient care. #ASCO #Oncology #Research #InternalMedicine #HematologyOncology #PGY1
Excited and honored to receive the Third Best Clinical Vignette Award along with a cash prize at Boston Medical Center Annual Research Day.
#AcademicMedicine #InternalMedicine #Hematology #Oncology #MedicalEducation #Research
immunotherapy, but he also underwent MR-guided SBRT targeting the IVC tumor thrombus. Follow-up imaging demonstrated significant regression of both the primary liver tumor and the IVC tumor thrombus.
This case highlights the impact of multidisciplinary collaboration and
ThE_uNKNowN retweeted
Sending my best wishes to IMGs who will find out their Match outcomes in two days.
ThE_uNKNowN retweeted
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: bit.ly/4pHA7EJ
ThE_uNKNowN retweeted
It’s not #ASH25 without an award show…
Presenting the Multiple Myeloma Golden Globules 🏆🩸-
voted on by absolutely no one except a budding-lymphoma doc😊 and a qualified myeloma doc🙌🏾 (both running on caffeine and #ASH adrenaline) 😅
#ASHDailyNews
ashpublications.org/ashnewsd…
ThE_uNKNowN retweeted
Yesterday’s Plenary highlighted important new insights into the biology of DLBCL in African American patients. Catch our full coverage — including key data and expert quotes — in today’s #ASHNewsDaily. #ASH25
ashpublications.org/ashnewsd…
ThE_uNKNowN retweeted
It was a great experience working and learning from this dream team! Special shoutout to the excellent ASH Staffs that made everything seamless!
#ASH25
It’s been a lot of fun acting as @JoselleCookMD's deputy in bringing #ASH25 ASHNewsDaily to life! Great to finally meet the team IRL today 😍
@ZanwarSaurabh
@EmperorBlackMD
@majorajay
@ChrisGrahamMD
@supriyaguptaMD
@ASH_hematology
ThE_uNKNowN retweeted
Still energized after my first @AmCollegeGastro meeting. A truly enriching learning experience and a great chance to reconnect with peers and mentors in GI. Proud to have received the #ACG2025 Outstanding Poster Presenter Award. Grateful to @OBHBrookdaleIM for the steady support.
ThE_uNKNowN retweeted
Just wrapped up a 3 day inspiring conference on transforming healthcare in Nigeria through tech & innovation(UNIMED),
Presented my research for the first time & it was an incredible opportunity to engage with brilliant minds driving change in our healthcare system.




































